Results 271 to 280 of about 27,849,568 (325)

Poslovni načrt podjetja IB d. o. o.

, 2016
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Dilemma in post-IBD patients with IBS-D symptoms: A 2020 overview

Expert Review of Gastroenterology & Hepatology, 2020
Inflammatory bowel disease (IBD) patients in apparent clinical remission who present with irritable bowel syndrome (IBS)-like symptoms pose a diagnostic and therapeutic dilemma that is called post-IBD IBS. When associated with a diarrheal IBS presentation, this clinical syndrome is known as post-IBD IBS-D.We review and describe the literature regarding
Mukaddes, Tozlu, Brooks, Cash, Mamoun, Younes, Atilla, Ertan   +3 more
openaire   +3 more sources

The mechanisms of action of WeiChang'An Pill (WCAP) treat diarrhoea-predominant irritable bowel syndrome (IBS-D) using network pharmacology approach and in vivo studies.

Journal of Ethnopharmacology, 2021
ETHNOPHARMACOLOGICAL RELEVANCE WeiChang'An Pill (WCAP) is used in Traditional Chinese Medicine (TCM) to clinically treat diarrhoea-predominant irritable bowel syndrome (IBS-D); however, the underlying pharmacological mechanisms are unclear to date. AIM
Yan Chen, Fuhao Chu, Jie Lin, Zeqi Su, Mengting Liao, Tao Li, Yuan Li, N. Johnson, Haocheng Zheng, Xia Ding   +9 more
semanticscholar   +1 more source

Novel Therapies in IBS-D Treatment

Current Treatment Options in Gastroenterology, 2015
Irritable bowel syndrome (IBS) is a common gastrointestinal disease characterized by abdominal pain and change in bowel habits. IBS diarrhea predominant (IBS-D), which is arguably the most common subset of IBS, is also associated with rectal urgency, increased frequency, abdominal bloating, and loose to watery stools.
Judy, Nee, Mohammed, Zakari, Anthony J, Lembo   +2 more
openaire   +2 more sources

No benefit of faecal microbiota transplantation for IBS-D

Drug and Therapeutics Bulletin, 2020
Abstract Review of: Aroniadis OC, Brandt LJ, Oneto C, et al. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol 2019;4:675–85.
openaire   +2 more sources

▼ Eluxadoline for IBS-D

Drug and Therapeutics Bulletin, 2017
Irritable bowel syndrome (IBS) is a chronic relapsing gastrointestinal problem characterised by intestinal pain and associated alterations of defecation and/or bowel habit (constipation: IBS-C or diarrhoea: IBS-D).1,2 Opioid receptors in the gut have a role in gastrointestinal motility, secretion and sensation.3 Τ Eluxadoline (Truberzi-Allergan) is a ...
openaire   +2 more sources

Editorial: ondansetron for patients with IBS‐D and bowel‐predominant symptoms

Alimentary Pharmacology & Therapeutics, 2023
LINKED CONTENTThis article is linked to Gunn et al papers.
openaire   +2 more sources

Chang-Kang-Fang alleviates diarrhea predominant irritable bowel syndrome (IBS-D) through inhibiting TLR4/NF-κB/NLRP3 pathway.

Journal of Ethnopharmacology
ETHNOPHARMACOLOGICAL RELEVANCE Chang-Kang-Fang (CKF), originated from traditional Chinese medicine (TCM) formulas, has been utilized to treat diarrhea predominant irritable bowel syndrome (IBS-D) based on clinical experience.
Si-Yu Zhang, Danmei Tian, Zi-Xuan Xia, Feng-Ge Yang, Yanhui Chen, Zhi-Hong Yao, Yi He, Xinglong Miao, Gui-Rong Zhou, Xin-Sheng Yao, Jinshan Tang   +10 more
semanticscholar   +1 more source

Evaluation of treatment continuation with alosetron by IBS-D severity criteria

Current Medical Research and Opinion, 2012
This article evaluates the characteristics and treatment patterns of female patients with severe diarrhea-predominant irritable bowel syndrome (IBS-D) who were treated with alosetron under a risk management program.Patients prescribed alosetron (2002-2009) and who voluntarily enrolled in the follow-up study were evaluated.
Jean Paul, Nicandro, Paul, Shin, Emil, Chuang   +2 more
openaire   +2 more sources

Perhaps it is time to rethink IBS-D

Scandinavian Journal of Gastroenterology, 2011
To the Editor: Diarrhea predominate irritable bowel syndrome (IBS-D) currently constitutes the largest sub-category of IBS causing a significant emotional and economic impact [1].
openaire   +2 more sources